CHECKING THE PULSE – RECENT LEGAL DEVELOPMENTS IN THE INDIAN HEALTHCARE AND PHARMA SECTOR

Over the past couple of months, the National Health Authority has taken active steps to successfully implement the Ayushman Bharat Digital Mission and drive the cause of digital health in India forward. In addition, significant amendments to the New Drugs and Clinical Trials Rules, 2019, blanket ban on the manufacture and sale of pain relief drug S(+) Etodolac + Paracetamol, and formulation of draft guidelines on good manufacturing practices for pharmaceutical products dominated the headlines in this space. Against this backdrop, INDUSLAW’s Shantanu Jindel, Shweta Gupta, Kriti Saraswat, Harshit Kumar, Vatsal Agarwal and Abhinav present you this edition of ‘Checking the Pulse’, delving into key updates from August 2024 to September 2024 in the healthcare and pharmaceutical sectors, while also tapping on notable deals that have gained interest from the industry.